Table 1.
Patient characteristics.
| Characteristics | 2nd vaccination | 3rd vaccination |
|---|---|---|
| Age, year, mean (SD) | 54.0 (12.4) | 51.5 (13.7) |
| Sex, no. (%) | ||
| Male | 11 (50) | 3 (18.8) |
| Female | 11 (50) | 13 (81.2) |
| Diagnosis, no (%) | ||
| Pemphigus vulgaris | 15 (68) | 16 (100) |
| Pemphigus foliaceus | 6 (30) | 0 (0) |
| Paraneoplastic pemphigus | 1 (5) | 0 (0) |
| Vaccination received, no. (%) | ||
| mRNA-based vaccine (mRNA-1273 or BNT162b2) |
17 (77.3) | 14 (87.5) |
| Non-mRNA-based vaccine (ChAdOx1-S) | 5 (22.7) | 2 (12.5) |
| Methylprednisolone dosage, median (IQR), mg/day | 1.6 (0-5.5) | 1.2 (0-5.0) |
| Azathioprine dosage, median (IQR), mg/day | 50 (0-75) | 15 (0-50) |
| Previous rituximab use, no. (%) | 13 (59.1) | 7 (43.8) |
| Peripheral B-cell percentage, % (SD) | 8.1 (8.4) | 8.6 (7.8) |
| Peripheral B-cell count, cell/μL (SD) | 136.9 (156.5) | 333.9 (550.1) |
| Peripheral B-cell deficiency, no. (%) | 7 (31.8) | 3 (18.8) |
| Antibody responses, median (IQR), AU/ml | 1401.6 (197.8-2543.9) |
6403.5 (2424.2-11306.2) |
| Adequate antibody response, no. (%) | 11 (50) | 14 (87.5) |
| T-cell responses, fold change (SD) | 1.82 (1.10) | 1.1 (1.4) |
| Adequate T-cell response, no. (%) | 6 (40) | 3 (20) |